Novavax Inc.

139.50+13.81+10.99%Vol 16.19M1Y Perf 2 780.21%
Nov 30th, 2020 16:00 DELAYED
BID139.50 ASK139.98
Open119.26 Previous Close125.69
Pre-Market118.72 After-Market-
 -6.97 -5.55%  - -
Target Price
186.20 
Analyst Rating
Strong Buy 1.50
Potential %
33.48 
Finscreener Ranking
★★★+ —    53.09
Insiders Trans % 3/6/12 mo.
-100/-97/-95 
Value Ranking
★★★ —    51.71
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     63.32
Insiders Shares Cnt. % 3/6/12 mo.
-100/-99/-98 
Income Ranking
 —    -
Market Cap8.88B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
73.14 
Earnings Date
9th Nov 2020

Today's Price Range

118.50147.50

52W Range

3.65189.40

5 Year PE Ratio Range

-15.20-1.70

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
46.33%
1 Month
72.84%
3 Months
32.76%
6 Months
164.10%
1 Year
2 780.21%
3 Years
387.76%
5 Years
-18.42%
10 Years
208.63%

TickerPriceChg.Chg.%
NVAX139.5013.810010.99
AAPL119.052.46002.11
GOOG1 760.74-32.4500-1.81
MSFT214.07-1.1600-0.54
XOM38.13-2.0600-5.13
WFC27.35-1.1100-3.90
JNJ144.680.68000.47
FB276.97-0.8400-0.30
GE10.18-0.2200-2.12
JPM118.85-2.3700-1.96
Financial StrengthValueIndustryS&P 500US Markets
2.20
2.80
0.78
4.14
-19.60
Leverage Ratio 30.90
ProfitabilityValueIndustryS&P 500US Markets
-
-126.60
-124.70
-819.20
-
RevenueValueIndustryS&P 500US Markets
204.76M
3.22
45.60
20.41
Earnings HistoryEstimateReportedSurprise %
Q03 20202.36-3.21-236.02
Q02 2020-0.57-0.3047.37
Q01 2020-0.67-0.5813.43
Q04 2019-1.08-1.13-4.63
Q03 2019-1.02-1.03-0.98
Q02 2019-1.61-1.69-4.97
Q01 2019-2.40-2.208.33
Q04 2018-2.40-2.60-8.33
Earnings Per EndEstimateRevision %Trend
12/2020 QR-1.90-131.10Negative
12/2020 FY-5.40-128.45Negative
3/2021 QR-1.59-121.81Negative
12/2021 FY14.40--
Next Report Date-
Estimated EPS Next Report2.36
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume16.19M
Shares Outstanding63.66M
Trades Count183.80K
Dollar Volume2.18B
Avg. Volume7.54M
Avg. Weekly Volume8.13M
Avg. Monthly Volume4.75M
Avg. Quarterly Volume4.40M

Novavax Inc. (NASDAQ: NVAX) stock closed at 139.5 per share at the end of the most recent trading day (a 10.99% change compared to the prior day closing price) with a volume of 16.38M shares and market capitalization of 8.88B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 168 people. Novavax Inc. CEO is Stanley Charles Erck.

The one-year performance of Novavax Inc. stock is 2780.21%, while year-to-date (YTD) performance is 3405.03%. NVAX stock has a five-year performance of -18.42%. Its 52-week range is between 3.65 and 189.4, which gives NVAX stock a 52-week price range ratio of 73.14%

Novavax Inc. currently has a PE ratio of -24.30, a price-to-book (PB) ratio of 75.17, a price-to-sale (PS) ratio of 31.90, a price to cashflow ratio of 97.10, a PEG ratio of 2.32, a ROA of -48.61%, a ROC of -38.46% and a ROE of 557.43%. The company’s profit margin is -%, its EBITDA margin is -124.70%, and its revenue ttm is $204.76 Million , which makes it $3.22 revenue per share.

Of the last four earnings reports from Novavax Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $2.36 for the next earnings report. Novavax Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Novavax Inc. is Strong Buy (1.5), with a target price of $186.2, which is +33.48% compared to the current price. The earnings rating for Novavax Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Novavax Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Novavax Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.05, ATR14 : 8.06, CCI20 : -69.97, Chaikin Money Flow : -0.21, MACD : -5.50, Money Flow Index : 59.02, ROC : -5.11, RSI : 42.77, STOCH (14,3) : 34.21, STOCH RSI : 0.59, UO : 41.67, Williams %R : -65.79), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Novavax Inc. in the last 12-months were: Gary C. Evans (Option Excercise at a value of $430 600), Gary C. Evans (Sold 21 000 shares of value $3 159 240 ), Gregory Glenn (Buy at a value of $4 825), Gregory Glenn (Option Excercise at a value of $0), Gregory M. Glenn (Buy at a value of $4 825), Gregory M. Glenn (Option Excercise at a value of $2 732 083), Gregory M. Glenn (Sold 117 619 shares of value $14 009 263 ), James F. Young (Buy at a value of $146 490), John A. Herrmann (Option Excercise at a value of $5 950 647), John A. Herrmann (Sold 203 964 shares of value $23 958 640 ), John J. Trizzino (Option Excercise at a value of $4 712 212), John J. Trizzino (Sold 176 718 shares of value $22 674 539 ), Michael A. Mcmanus (Option Excercise at a value of $220 800), Michael A. Mcmanus (Sold 16 000 shares of value $2 336 000 ), Stanley Charles Erck (Option Excercise at a value of $148 750), Stanley Charles Erck (Sold 38 445 shares of value $4 234 007 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
6 (85.71 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (25.00 %)
1 (14.29 %)
2 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.29
Moderate Buy
1.57

Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

CEO: Stanley Charles Erck

Teplephone: +1 240 268-2000

Address: 20 Firstfield Road, Gaithersburg 20878, MD, USA

Number of employees: 168

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

47%53%

News

Stocktwits